Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. | Amal El Beshlawy

Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

Citation:: Mistry, P. K., M. Balwani, H. N. Baris, H. B. Turkia, A. T. Burrow, J. Charrow, G. F. Cox, S. Danda, M. Dragosky, G. Drelichman, et al., "Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.", Blood cells, molecules & diseases, vol. 77, pp. 101-102, 2019.